1. Platformization is a major trend:Aidoc has evolved from a single-product model of “one AI algorithm for one disease” to a platform model where “one foundational model covers dozens of acute conditions.” Leading domestic companies such as United Imaging Intelligence (with a cumulative total of 20 Class III medical device registrations) and Shukun Technology (with 19 Class III registrations) are following similar paths. The key to competition in the next phase lies in achieving multi-disease and multi-modal coverage within a single framework.

2. AI Report Writing Is Set to Become the Main Battleground:The emergence of First Read marks AI’s transition from “assisted diagnosis” to “assisted report drafting.” Radiology report turnaround times in the United States have doubled, and there is a severe shortage of personnel; similarly, the Chinese market faces challenges due to an insufficient number of radiologists. However, the “hallucination” issue associated with generative AI (with leading models still exhibiting a hallucination rate of 51.7% in testing) necessitates retaining final physician review authority throughout the entire workflow.

3. The FDA is creating a new classification for AI devices:In June 2026, the FDA added the product code QXO for “Cardiovascular Machine Learning Notification Software” (Class II, 510(k) pathway), indicating that the regulatory agency is establishing an independent classification framework for AI/ML devices. Companies expanding into overseas markets should closely monitor FDA classification developments and promptly adjust their registration strategies.

4. Reference for Compliance Pathways:Aidoc’s strategy is to first secure single-product 510(k) clearances (with 18 approvals already obtained), and then leverage Breakthrough Device Designation to accelerate platform-level regulatory approval. Chinese companies expanding overseas can reference this “step-by-step” FDA compliance strategy: first validate technical capabilities with individual products, then apply for Breakthrough Device Designation to access an accelerated review pathway, and ultimately achieve platform-wide product coverage.

Powered by CARE™ – the first clinical-grade foundation model in healthcare with FDA cleared solutions, built to solve one of the most critical bottlenecks in health systems

Aidoc, the global leader in clinical AI, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's novel multi-triage solution that flags a wide array of life-threatening, time-sensitive medical conditions, all within a single workflow. Built on CARE™, the first clinical-grade foundation model in healthcare with FDA cleared solutions, and deployed through Aidoc's aiOS™ platform, the solution is designed to help care teams attend to high-risk cases faster and more consistently across the health system.

This is the first-ever designation for AI with such broad coverage of medical conditions under one solution. The FDA grants Breakthrough Device Designation to technologies that both significantly advance the diagnosis of severe diseases and represent an unmet clinical need. The designation is intended to accelerate access to life-saving innovations by expediting the review process. In this case, it enables parallel review of double-digit indications within a single submission, an important step toward bringing comprehensive, high-accuracy clinical AI to routine care while maintaining robust safety and effectiveness standards.

"With this designation and our ecosystem of specialized partners, we can deliver a broader set of solutions across many service lines. CARE's ability to detect, characterize, measure, and compare findings underpins both current and in-development applications from triage to report drafting," said Elad Walach, co-founder and CEO, Aidoc. "We are tackling this from multiple angles, developing innovations in parallel and, as each is FDA cleared, bringing it to market – delivering valuable, safe solutions while building toward the next milestone."

Emergency departments and inpatient units are stuck in a vicious cycle. Rising patient volumes and a worsening shortage of physicians and nurses strain capacity, reducing efficiency and slowing care. Radiology is central: escalating imaging demand pushes radiology departments to their limits, creating delays that cascade downstream. Wait times are rising – in 2024, over one in four admitted patients waited four or more hours for a bed, with many waiting beyond 24 hours – and quality suffers as care continues under pressure. Comprehensive AI-powered triage can help break this cycle by flagging urgent cases and streamlining workflows to restore flow across the ED.

Aidoc has already become an essential tool for improving efficiency and care quality across health systems worldwide. With the most FDA-cleared AI indications in its category, Aidoc has scaled its impact across numerous disease states, all designed to accelerate patient care and ensure consistent quality at scale. Historically, these advancements expanded one condition at a time. CARE shifts this by enabling broad, simultaneous coverage across many pathologies. Clearance for multi-use systems covering tens of pathologies is complex and unprecedented, prompting renewed attention to design, development, and validation frameworks.

"The technology creates an extraordinary opportunity to advance healthcare, but success depends on more than the AI itself. It's about how it integrates, what data it can access, how it interacts with users, and how change is managed – ultimately ensuring patients are treated faster and better," said Michael Braginsky, co-founder and CTO, Aidoc. "It's a massive lift, but by leveraging the expertise and infrastructure we've built over the years, we're turning this vision into reality."

How It Works: CARE™ (Clinical AI Reasoning Engine) is specifically designed for clinical use, and trained on an enormous amount of real-world multimodal data to safely expand across diseases and care settings. Along with aiOS™, Aidoc's enterprise platform, health systems can integrate AI into existing workflows, manage performance, and deploy both Aidoc and third-party AI models across various service lines.

What's Next: The Breakthrough milestone advances Aidoc's roadmap toward a comprehensive, integrated clinical AI package, with additional CARE-powered capabilities such as auto-creation of draft reports, already in development. Aidoc's momentum includes 18 FDA clearances, deployments across over 150 U.S. health systems and more than 1,600 hospitals worldwide, as well as collaborations with Nvidia and AWS, with over $150 million committed to CARE's development and deployment.